Edition:
United States

Rexahn Pharmaceuticals Inc (RNN)

RNN on American Stock Exchange

0.17USD
19 Jan 2017
Change (% chg)

-- (--)
Prev Close
$0.17
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,289,758
52-wk High
$0.42
52-wk Low
$0.13

Select another date:

Mon, Nov 7 2016

BRIEF-Rexahn Pharmaceuticals reports Q3 loss per share of $0.01

* Rexahn Pharma - expects cash, investments as of Sept 30, 2016 to be sufficient to fund cash flow requirements for activities into first half of 2018

BRIEF-Rexahn Pharmaceuticals says received notice of allowance from U.S PTO

* Received notice of allowance from U.S PTO for a patent for claims related to synthesis of its novel anti-cancer investigational drug candidate, rx-3117 Source text for Eikon: Further company coverage:

BRIEF-Rexahn Pharmaceuticals presents preliminary efficacy data from phase Ib/IIa trial of RX-3117, Supinoxin phase I trial

* Rexahn Pharmaceuticals presents preliminary efficacy data from phase Ib/IIa trial of RX-3117 in metastatic pancreatic cancer and supinoxin phase I trial at 2016 European Society For Medical Oncology (ESMO) congress

BRIEF-Rexahn Pharmaceuticals announces $6 million registered direct offering

* Rexahn Pharmaceuticals -Rexahn announces $6 million registered direct offering Source text:

BRIEF-Rexahn Pharmaceuticals Q2 loss per share $0.01

* Rexahn Pharmaceuticals reports second quarter 2016 financial and operational results

Select another date: